Monoclonal Antibody Therapeutics (mABs) Market Growth Overview, Size, Future Trends, Share, Opportunities and Forecast to 2030

The Monoclonal Antibody Therapeutics (mABs) Market size is expected to grow from US$ 192.043 billion in 2022 to US$ 542.801 billion by 2030; it is expected to grow at a CAGR of 13.9% from 2022 to 2030.

Production of mABs-based drugs to treat several diseases are a few factors driving the monoclonal antibody therapeutics (mAbs) market growth.

A monoclonal antibody (mAbs) drug is a homogenous collection of antibodies having specificity toward selected target antigens. The production process of therapeutic mAbs requires a mammalian expression system offering the cell machinery essential to glycosylate, fold, orient, and covalently bind antibody peptide chains to produce complete and biologically functional molecules. New modality antibodies such as bispecific and trispecific antibodies recognize multiple epitopes on a single antigen, while single-domain antibodies can penetrate tissues with greater ease. Such advanced antibody types can enhance the efficiency of the antibody therapeutics, thereby expanding their application areas.

These antibodies can also form antibody-drug conjugates to improve the efficiency of chemotherapy agents in targeting specific cell types. Production of mAB-based drugs to treat several diseases propel the market development. Innovative product launches through strategic developments by the manufacturers act as lucrative market opportunity. Furthermore, combination drugs containing mABs acts as a market trend for mAbs therapeutic market.

Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00083471?utm_source=OpenPr&utm_medium=10640

Analysis of the Top Market Players:

1. GlaxoSmithKline
2. F.Hoffmann-La-Roche
3. Bayer AG
4. Amgen
5. Novartis
6. AbbVie
7. Bristol-Myers Squibb
8. Janssen Pharmaceutical
9. Merck KgaA
10. AstraZeneca

In this report, the market has been segmented on the basis of:

Product
• Recombinant MABs
• Antibody Drug Conjugates
• Bispecific And Multispecific MABs
• Biosimilars

Application
• Oncology
• Autoimmune Disease

Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies

Get full Report Description, TOC, Table of Figure, Chart, etc. @: https://www.premiummarketinsights.com/reports-tip/monoclonal-antibody-therapeutics-mabs-market

Innovative Product Launches Through Strategic Developments by Manufacturers

Organic developments such as product launches by the manufacturers of therapeutic mABs are likely to bolster the monoclonal antibody therapeutics (mABs) market in the coming years. In March 2022, Adagio Therapeutics, Inc. announced the launch of ADG20 (ADINTREVIMAB). The newly launched product is the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment for COVID-19 by seeking US Emergency Use Authorization (EUA).

Further, inorganic developments such as mergers and acquisitions would result in the introduction of new therapeutic mABs. For instance, in July 2023, Elli Lilly announced the acquisition of Versanis, a private clinical-stage biopharmaceutical company intended to treat cardiometabolic diseases. Elli Lilly acquired Versanis to access its core product portfolio, including a monoclonal antibody product named bimagrumab. This product is currently being assessed in the "BELIEVE Phase 2b study" as a standalone molecule. It is also being studied in combination with semaglutide for its combined potential to reduce fat mass, preserve muscle mass, and deliver better patient outcomes in people living with obesity and obesity-related complications. The aforementioned factors are responsible for influential monoclonal antibody therapeutics (mABs) market growth in the coming years.

Buy this research report at @: https://www.premiummarketinsights.com/buy/TIP00083471?utm_source=OpenPr&utm_medium=10640

Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
Email: sales@premiummarketinsights.com

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

This release was published on openPR.